BiotechTube

AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bioavailability and AUC

Conditions

Bioavailability and AUC

Trial Timeline

Aug 1, 2012 → Dec 1, 2012

NCT ID
NCT01635985

About AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423

AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 + AZD5423 is a phase 1 stage product being developed by AstraZeneca for Bioavailability and AUC. The current trial status is completed. This product is registered under clinical trial identifier NCT01635985. Target conditions include Bioavailability and AUC.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01635985Phase 1Completed

Competing Products

20 competing products in Bioavailability and AUC

See all competitors
ProductCompanyStageHype Score
solifenacin succinate suspension + solifenacin succinate tabletAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
ASP015KAstellas PharmaPhase 1
33
IpragliflozinAstellas PharmaPhase 1
33
HetrombopagJiangsu Hengrui MedicinePhase 1
33
ABT-450/r/ABT-267AbbViePhase 1
33
ABT-333AbbViePhase 1
33
Treatment A- Part 1 + Treatment B- Part 1 + Treatment C - Part 1 + Treatment D- Part 1 + Treatment A-Part 2 + Treatment B - Part 2 + Treatment C - Part 2 + Treatment D - Part 2AstraZenecaPhase 1
33
Naloxegol 25 mg tablet, crushed, suspended in water, given orally + Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube + Naloxegol 25 mg (10 mL oral solution) + Naloxegol 25 mg tablet, given orallyAstraZenecaPhase 1
33
selumetinib 75mg single dose + selumetinib 75mg single dose + selumetinib 75mg single doseAstraZenecaPhase 1
33
selumetinib 75mg single doseAstraZenecaPhase 1
33
Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tubeAstraZenecaPhase 1
33
Fostamatinib + Fostamatinib + Fostamatinib + FostamatinibAstraZenecaPhase 1
33
BDA MDI 160/180 mcg + Pulmicort Flexhaler 180 mcgAstraZenecaPhase 1
33
D1400147 + D14000136 + D14000137 + Epanova®AstraZenecaPhase 1
33
Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water + Ticagrelor OD tablet (90 mg single dose) administered without water + Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube + Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of waterAstraZenecaPhase 1
33
NKTR-118 + KetoconazoleAstraZenecaPhase 1
33
TEPEZZA + EDPAmgenPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavirPfizerPhase 1
32
PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332/ritonavir + PF-07321332PfizerPhase 1
32

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85